dataesr/scientific-paragraphs-categorization huggingface dataset:
A master spectrum was generated by averaging the blaze-corrected spectra from individual nights, and the envelope was used to create a continuum normalisation that was then applied to all spectra. Finally, we used Least-Squares Deconvolution, based on  Donati et al. (1997)  as implemented by  Watson et al. (2006) , to combine the signal from the multiple stellar lines and increase the signalto-noise ratio. Care was taken to mask both bands with strong telluric residuals (e. g. the saturated O 2 bands in the red arm) as well as wavelength regions that are strongly affected by stellar emission features (e. g. the Balmer lines, Ca II H&K lines, the Na D lines) due to accretion. The linelist of ∼ 2400 lines was generated using the 'Extract Stellar' option from the VALD3 database  (Ryabchikova et al.
ACKNOWLEDGEMENTS This research made use of Astropy, 10 a communitydeveloped core Python package for Astronomy (Astropy Collaboration et al. 2013;Price-Whelan et al. 2018) and of  Matplotlib  (Hunter 2007). We thank our anonymous referee for their helpful comments. We acknowledge with thanks the variable star observations from the AAVSO International Database contributed by observers worldwide and used in this research. HPO acknowledges support from  Centre National d'Etudes Spatiales (CNES)  grant  131425-PLATO. M. H. thanks  Frank (Theo) Matthai  for assistance with finding the relevant Sonneberg plates in the observatory archive. This work has made use of the VALD database, operated at  Uppsala University , the  Institute of Astronomy RAS in Moscow , and the  University of Vienna. E. H. acknowledges support by the  Spanish Ministry of Economy and Competitiveness (MINECO)  and the  Fondo Europeo de Desarrollo Regional (FEDER)  through grant  ESP2016-80435-C2-1-R , as well as the support of the  Generalitat de Catalunya/CERCA  programme.
ASAS-SN light curves are primarily funded by  Gordon & Betty Moore Foundation  under grant  GBMF5490. M. N. G. is supported by the  STFC  award reference 1490409 as well as the  Isaac Newton Studentship. L. M. acknowledges support from the  Italian Minister of Instruction, University and Research (MIUR)  through  FFABR 2017  fund. L. M. acknowledges support from the  University of Rome Tor Vergata  through " Mission: Sustainability 2016 " fund. The NGTS instrument and operations are funded by the  University of Warwick , the  University of Leicester, Queen's University Belfast , the  University of Geneva , the  Deutsches Zentrum für Luft-und Raumfahrt  e. V. (DLR; under the ' Großinvestition GI-NGTS '), the  University of Cambridge  and the  UK STFC  (project reference  ST/M001962/1 ). P. J.
Case-control analyses We analyzed the association of three FANCM truncating variants, p. Arg658*, p. Gln1701*, and p. Arg1931*, with breast cancer risk for each variant separately and using a burden analysis. We tested 67,112 invasive breast cancer cases and 53,766 controls collected by the Breast Cancer Association Consortium (BCAC, http://bcac. ccge. medschl. cam. ac. uk/) and 26,662 carriers of BRCA1 or BRCA2 pathogenic variants collected by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, http://cimba. ccge. medschl. cam. ac. uk/), of whom 13,497 were affected with breast cancer and 13,165 were unaffected. In the BCAC dataset we assessed the breast cancer risk associated with the FANCM variants in a primary overall analysis and in a restricted analysis including only countries in which the variant carrier frequencies were higher than the median of the frequencies.
For each study subject, information on the disease status and the age at diagnosis or at interview were provided. Data on lifestyle risk factors were available for most subjects and clinical and pathological data were available for most cases. All these data were incorporated in the BCAC dataset (version 10). A total of 44,565 (66%) cases were ER-positive, 10,770 (16%) were ER-negative, and 4,805 (7%) were TNBC; 13,743 (20%) had a positive first-degree family history of breast cancer. The CIMBA studies contributed 15,679 carriers of a pathogenic BRCA1 variant and 10,983 carriers of a pathogenic BRCA2 variant to this analysis (Supplementary Table  5 ). Nearly all (98%) of these carriers were ascertained through cancer genetic clinics; few carriers were recruited by populationbased sampling of cases or by community recruitment.
Statistical analyses The BCAC data were analyzed to test the association between FANCM:p. Arg658*, p. Gln1701*, and p. Arg1931* and breast cancer risk. Logistic regression analyses were performed to estimate ORs with 95% CIs for variant carriers versus non-carriers, adjusting for country and the first ten principal components, as previously described. 19 P-values were calculated by applying the likelihood ratio test (LRT) comparing the model containing the variant carrier status as a covariate to a model without the variant carrier status. The primary analyses were performed including all invasive breast cancer cases and controls and subgrouping cases based on tumor hormonal status. We then performed a country-restricted analysis including the 50% of the countries with the higher variant carrier frequencies.
Specifically, we included only countries in which the carrier frequencies in cases and controls combined were higher than the median of the carrier frequencies observed in all countries. Median frequencies were 0. 007, 0. 114 and 0. 163 for p. Arg658*, p. Gln1701* and p. Arg1931* carriers, respectively. The CIMBA data were analyzed to evaluate the association between each FANCM truncating variant and breast cancer risk in carriers of BRCA1 or BRCA2 pathogenic variant. A survival analyses framework was applied. Briefly, each variant carrier was followed from the age of 18 years until the first breast cancer diagnosis, or censored as unaffected at ovarian cancer diagnosis, bilateral prophylactic mastectomy, or age at last follow-up. The analyses were performed by modelling the retrospective likelihood of the observed genotypes conditional on the disease phenotype as detailed previously.
20 All analyses were stratified for country. The per-allele hazard ratio (HR), 95% CIs were estimated separately for each variant. A score test was used to derive P-values for the associations. The analyses of the BCAC data were performed using STATA version 15 (StataCorp LLC, College Station, Texas, USA). The analyses of the CIMBA data were carried out using custom-written code in Python and Fortran. All statistical tests were twosided and P-values <0. 05 were considered statistically significant.
DATA AVAILABILITY A subset of the genotype data analysed in this study is publicly available from the dbGaP repository and can be accessed at https://identifiers. org/dbgap:phs001265. v1. p1 (data generated as part of the BCAC studies) and at https://identifiers. org/dbgap: phs001321. v1. p1 (data generated as part of the CIMBA studies). The remaining genotype data analysed in this study (and generated as part of the BCAC and CIMBA studies listed in Supplementary Tables  4  and 5  of the related article, respectively) are not publicly available due to restraints imposed by the ethics committees of individual studies, but can be accessed from the corresponding author on reasonable request as described at https://doi. org/10. 6084/m9. figshare. 8982296. 22 Additional datasets generated during this study (and supporting Fig.
1  and Supplementary Tables  2  and 3  in the published article) are available on request as described above. The data generated and analyzed during this study are described in the following data record: https://doi. org/10. 6084/m9. figshare. 8982296. 22 erdes for the recruitment and genetic counseling of participants; Alicia Barroso, Rosario Alonso and Guillermo Pita; all the individuals and the researchers who took part in CONSIT TEAM (Consorzio Italiano Tumori Ereditari Alla Mammella), thanks in particular: Giulia Cagnoli, Roberta Villa, Irene Feroce, Mariarosaria Calvello, Riccardo Dolcetti, Giuseppe Giannini, Laura Papi, Gabriele Lorenzo Capone, Liliana Varesco, Viviana Gismondi, Maria Grazia Tibiletti, Daniela Furlan, Antonella Savarese, Aline Martayan, Stefania Tommasi, Brunella Pilato, Isabella Marchi, Elena Bandieri, Antonio Russo, Daniele Calistri and the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy.
and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). The BCEES was funded by the National Health and Medical Research Council, Australia and the Cancer Council Western Australia. For the BCFR-NY, BCFR-PA, BCFR-UT this work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. BCINIS study was funded by the BCRF (The Breast Cancer Research Foundation, USA). The BREast Oncology GAlician Network (BREOGAN) is funded by Acción Estratégica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Acción Estratégica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur.
CBCS is funded by the Canadian Cancer Society (grant # 313404) and the Canadian Institutes of Health Research. CCGP is supported by funding from the University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Sécurité Sanitaire, de l'Alimentation, de l'Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort. The CTS was initially supported by the California Breast Cancer Act of 1993 and the California Breast Cancer Research Fund (contract 97-10500) and is currently funded through the National Institutes of Health (R01 CA77398, K05 CA136967, UM1 CA164917, and U01 CA199277).
Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The University of Westminster curates the DietCompLyf database funded by Against Breast Cancer Registered Charity No. 1121258 and the NCRN. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos.
Robert Nussbaum, Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco and Peggy Conrad and Salina Chan; Carole Pye, Patricia Harrington and Eva Wozniak. OSUCCG thanks Kevin Sweet, Caroline Craven, Julia Cooper, Michelle O'Conor and Amber Aeilts. BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and by the European Community´s Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministère de l'Économie, Science et Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the Quebec Breast Cancer Foundation.
The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The AHS study is supported by the intramural research program of the National Institutes of Health, the National Cancer Institute (grant number Z01-CP010119), and the National Institute of Environmental Health Sciences (grant number Z01-ES049030). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breast Cancer Now.
ACKNOWLEDGEMENTS Peterlongo laboratory is supported by  Associazione Italiana Ricerca sul Cancro  (AIRC; IG2015 no. 16732 ) to  P. Peterlongo  and by a fellowship from  Fondazione Umberto Veronesi  to  G. Figlioli. Surrallés  laboratory is supported by the  ICREA-Academia program , the  Spanish Ministry of Health  (projects FANCOSTEM and FANCOLEN), the  Spanish Ministry of Economy and Competiveness  (projects  CB06/07/0023  and  RTI2018-098419-B-I00 ), the  European Commission  ( EUROFANCOLEN  project  HEALTH-F5-2012-305421  and P-SPHERE  COFUND  project), the  Fanconi Anemia Research Fund Inc , and the  "Fondo Europeo de Desarrollo Regional, una manera de hacer Europa" (FEDER). CIBERER is an initiative of the  Instituto de Salud Carlos III, Spain. BCAC: we thank all the individuals who took part in these studies and all the researchers, clinicians, technicians and administrative staff who have enabled this work to be carried out.
The NBHS was supported by  NIH  grant  R01CA100374. Biological sample preparation was conducted the  Survey and Biospecimen Shared Resource , which is supported by  P30 CA68485. The  Northern California Breast Cancer Family Registry (NC-BCFR)  and  Ontario Familial Breast Cancer Registry (OFBCR)  were supported by grant  UM1 CA164920  from the  National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the  National Cancer Institute  or any of the collaborating centers in the  Breast Cancer Family Registry (BCFR) , nor does mention of trade names, commercial products, or organizations imply endorsement by the  USA Government  or the BCFR. The Carolina Breast Cancer Study was funded by  Komen Foundation , the  National Cancer Institute  ( P50 CA058223 ,  U54 CA156733 ,  U01 CA179715 ), and the  North Carolina University Cancer Research Fund.
The NHS was supported by  NIH  grants  P01 CA87969 ,  UM1 CA186107 , and  U19 CA148065. The NHS2 was supported by  NIH  grants  UM1 CA176726  and  U19 CA148065. The ORIGO study was supported by the  Dutch Cancer Society  ( RUL 1997-1505 ) and the  Biobanking and Biomolecular Resources Research Infrastructure  ( BBMRI-NL CP16 ). The PBCS was funded by  Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the  Intramural Research Program  of the  National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the  Intramural Research Program of the Division of Cancer Epidemiology and Genetics  and supported by contracts from the  Division of Cancer Prevention, National Cancer Institute, National Institutes of Health.
The POSH study is funded by  Cancer Research UK  (grants  C1275/ A11699 ,  C1275/C22524 ,  C1275/A19187 ,  C1275/A15956  and  Breast Cancer Campaign   2010PR62 ,  2013PR044. PROCAS is funded from  NIHR  grant  PGfAR   0707-10031. The RBCS was funded by the  Dutch Cancer Society  ( DDHK 2004-3124 ,  DDHK 2009-4318 ). SEARCH is funded by  Cancer Research UK  [ C490/A10124 ,  C490/A16561 ] and supported by the  UK National Institute for Health Research Biomedical Research Centre  at the  University of Cambridge. The  University of Cambridge  has received salary support for PDPP from the  NHS in the East of England through the Clinical Academic Reserve. The Sister Study (SISTER) is supported by the  Intramural Research Program  of the  NIH, National Institute of Environmental Health Sciences  ( Z01-ES044005  and  Z01-ES049033 ).
The  Two Sister Study  ( 2SISTER ) was supported by the  Intramural Research Program  of the  NIH, National Institute of Environmental Health Sciences  ( Z01-ES044005  and  Z01-ES102245 ), and, also by a grant from  Susan G. Komen for the Cure , grant  FAS0703856. SKKDKFZS is supported by the  DKFZ. The SMC is funded by the  Swedish Cancer Foundation  and the  Swedish Research Council  [grant  2017-00644  for the Swedish Infrastructure for Medical Population-based  Lifecourse Environmental Research (SIMPLER) ]. The SZBCS is financially supported under the program of  Minister of Science and Higher Education "Regional Initiative of Excellence " in years  2019-2022 , Grant No  002/RID/2018/19. The TNBCC was supported by: a  Specialized Program of Research Excellence (SPORE) in Breast Cancer  ( CA116201 ), a grant from the  Breast Cancer Research Foundation , a generous gift from the  David F.
and Margaret T. Grohne Family Foundation. The UCIBCS component of this research was supported by the  NIH  [ CA58860 ,  CA92044 ] and the  Lon V Smith Foundation  [LVS39420]. The UKBGS is funded by  Breast Cancer Now  and the  Institute of Cancer Research (ICR), London. ICR  acknowledges  NHS  funding to the  NIHR Biomedical Research Centre. The UKOPS study was funded by  The Eve Appeal (The Oak Foundation ) and supported by the  National Institute for Health Research University College London Hospitals Biomedical Research Centre. The  USRT Study  was funded by  Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. CIMBA CIMBA: The CIMBA data management and data analysis were supported by  Cancer Research -UK  grants  C12292/A20861 ,  C12292/A11174.
P-MIP-19-164. BIDMC:  Breast Cancer Research Foundation. BMBSA: Cancer Association of South Africa  (PI Elizabeth J. van Rensburg). CNIO:  Spanish Ministry of Health   PI16/00440  supported by  FEDER  funds, the  Spanish Ministry of Economy and Competitiveness (MINECO)   SAF2014-57680-R  and the  Spanish Research Network on Rare diseases (CIBERER). COH-CCGCRN: Research reported in this publication was supported by the  National Cancer Institute of the National Institutes of Health  under grant number  R25CA112486 , and  RC4CA153828  (PI:  J. Weitzel ) from the  National Cancer Institute  and the Office of the Director,  National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
FHRISK is funded from  NIHR  grant  PGfAR   0707-10031. The  GC-HBOC (German Consortium of Hereditary Breast  and  Ovarian Cancer ) is supported by the  German Cancer Aid  (grant no  110837 , coordinator:  Rita K. Schmutzler , Cologne). This work was also funded by the  European Regional Development Fund and Free State of Saxony, Germany (LIFE -Leipzig Research Centre for Civilization Diseases , project numbers  713-241202 ,  713-241202 ,  14505/ 2470 ,  14575/2470 ). The GENICA was funded by the  Federal Ministry of Education and Research (BMBF)   Germany grants   01KW9975/5 ,  01KW9976/8 ,  01KW9977/0  and  01KW0114 , the  Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ) ,  Heidelberg , the  Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA) ,  Bochum , as well as the  Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.
E. K was supported by the program for support the bioresource collections  №007-030164/2  and study was performed as part of the assignment of the  Ministry of Science and Higher Education of Russian Federation  ( №АААА-А16-116020350032-1 ). Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between  Stockholm County Council and Karolinska Institutet , the  Swedish Cancer Society , The Gustav V Jubilee foundation and Bert von Kantzows foundation. The KARMA study was supported by  Märit and Hans Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government Funding (EVO) of  Kuopio University Hospital  grants,  Cancer Fund of North Savo , the  Finnish Cancer Organizations , and by the strategic funding of the  University of Eastern Finland.
LMBC is supported by the 'Stichting tegen Kanker'. DL is supported by the  FWO. The MABCS study is funded by the  Research Centre for Genetic Engineering  and  Biotechnology "Georgi D. Efremov " and supported by the  German Academic Exchange Program ,  DAAD. The MARIE study was supported by the  Deutsche Krebshilfe e. V. [ 70-2892-BR I, 106332 ,  108253 ,  108419 ,  110826 ,  110828 ], the  Hamburg Cancer Society , the  German Cancer Research Center (DKFZ)  and the  Federal Ministry of Education and Research (BMBF) Germany  [ 01KH0402 ]. MBCSG is supported by grants from the  Italian Association for Cancer Research (AIRC)  and by funds from the  Italian  citizens who allocated the 5/1000 share of their tax payment in support of the  Fondazione IRCCS Istituto Nazionale Tumori , according to Italian laws ( INT-Institutional strategic  projects "5 × 1000").
The MCBCS was supported by the  NIH  grants  CA192393 ,  CA116167 , CA176785 an  NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer  [ CA116201 ], and the  Breast Cancer Research Foundation  and a generous gift from the  David F. and Margaret T. Grohne Family Foundation. MCCS cohort recruitment was funded by  VicHealth  and  Cancer Council Victoria. The MCCS was further supported by Australian  NHMRC  grants  209057  and  396414 , and by infrastructure provided by  Cancer Council Victoria. Cases and their vital status were ascertained through the  Victorian Cancer Registry (VCR)  and the  Australian Institute of Health and Welfare (AIHW) , including the  National Death Index  and the Australian Cancer Database. The MEC was support by  NIH  grants  CA63464 ,  CA54281 ,  CA098758 ,  CA132839  and  CA164973.
FCCC:  NIH/NCI  grant  P30-CA006927. The  University of Kansas Cancer Center  ( P30 CA168524 ) and the  Kansas Bioscience Authority Eminent Scholar Program. A. K. G. was funded by  R0 1CA140323 ,  R01 CA214545 , and by the  Chancellors Distinguished Chair in Biomedical Sciences Professorship. Ana Vega  is supported by the  Spanish Health Research Foundation ,  Instituto de Salud Carlos III (ISCIII) , partially supported by  FEDER  funds through  Research Activity Intensification Program  (contract grant numbers:  INT15/00070 ,  INT16/00154 ,  INT17/00133 ), and through  Centro de Investigación Biomédica en Red de Enferemdades Raras CIBERER  ( ACCI 2016: ER17P1AC7112/2018 );  Autonomous Government of Galicia  (Consolidation and structuring program:  IN607B ), and by the  Fundación Mutua Madrileña  (call 2018).